Budesonide 0,125 Mg/Ml , 0,25 Mg/Ml & 0,5 Mg/Ml Respules Cipla 0,125 mg; 0,25mg & 0,5 mg Nebuliser Suspension
Clinical Summary
Quick overview from the medicine insert
Indication
Management of asthma and acute laryngotracheobronchitis-croup.
Dosage (summary)
Adults: 0.5 to 1 mg twice daily; Children: 0.25 to 1 mg twice daily based on previous therapy.
Onset of Action / Duration
Onset: 10 days, Duration: individual.
Special Populations
- Children under 12 months
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding not established; prefer inhaled over oral corticosteroids.
Key Drug Interactions
- CYP3A inhibitors (e.g., ketoconazole, itraconazole)
Contraindications
- Hypersensitivity to budesonide
- Active tuberculosis
- Fungal/viral infections in airways
Common side effects
- Oropharyngeal candidiasis
- Pneumonia in COPD patients
- Hoarseness
- Cough
Counselling Points
- Rinse mouth after use to prevent candidiasis
- Monitor for signs of adrenal insufficiency
- Use nebuliser as directed
Serious warnings
- Paradoxical bronchospasm
- Risk of adrenal insufficiency
- Potential for growth retardation in children
Important Disclaimer
The Budesonide 0,125 Mg/Ml , 0,25 Mg/Ml & 0,5 Mg/Ml Respules Cipla 0,125 mg; 0,25mg & 0,5 mg Nebuliser Suspension professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
